他汀类药物在肝癌治疗中的“双刃剑”作用及相关机制探讨

王方华; 赵稚博; 龚建平

doi:10.3969/j.issn.1001-5256.2020.09.042

他汀类药物在肝癌治疗中的“双刃剑”作用及相关机制探讨

DOI: 10.3969/j.issn.1001-5256.2020.09.042

1. 重庆市渝北区第二人民医院外科
2. 重庆医科大学附属第二医院肝胆外科

基金项目:

国家自然科学基金(81400614)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 583
- HTML全文浏览量: 14
- PDF下载量: 123
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Role of statins as a “double-edged sword” in treatment of liver cancer and related mechanisms

Department of Surgery, The Second People’s Hospital of Yubei District,

Research funding:

摘要

摘要:
在过去十年中,甲羟戊酸途径及其抑制剂他汀类药物在预防肿瘤发生及改善肿瘤预后方面的作用得到了广泛关注。然而,到目前为止,他汀类药物在肝癌中的作用仍然存在争议。前期研究证实,他汀类药物在胆固醇代谢、抗氧化及抗炎方面发挥重要作用。而胆固醇代谢、氧化应激及炎症反应则是促进肝癌发生发展的重要因素。但最近也有研究发现,他汀药物在部分肝癌患者治疗中存在相反的作用。对他汀药物在肝癌治疗中的"双刃剑"作用及其相关分子机制进行了阐述。
- 肝肿瘤 /
- 羟甲基戊二酰基CoA还原酶抑制剂 /
- 药物疗法
Abstract:
In the past decade,the role of the mevalonic acid pathway and its inhibitor statins in preventing tumorigenesis and improving tumor prognosis has attracted wide attention; however,so far,there are still controversies over the role of statins in liver cancer. Previous studies have shown that statins play an important role in cholesterol metabolism,antioxidation,and anti-inflammation,and cholesterol metabolism,oxidative stress,and inflammatory response are important factors to promote the development and progression of liver cancer. However,some recent studies have found that statins have an adverse effect on the treatment of some liver cancer patients. This article elaborates on the role of statins as a“double-edged sword”in the treatment of liver cancer and related molecular mechanisms.
- liver neoplasms /
- hydroxymethylglutaryl-CoA reductase inhibitors /
- drug therapy

HTML全文

参考文献(28)

[1] FATEHI HASSANABAD A. Current perspectives on statins as potential anti-cancer therapeutics:Clinical outcomes and underlying molecular mechanisms[J]. Transl Lung Cancer Res,2019,8(5):692-699.

[2] BUTT AA,YAN P,BONILLA H,et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons:Results from ERCHIVES[J]. Hepatology,2015,62(2):365-374.

[3] HSIANG JC,WONG GL,TSE YK,et al. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population:A propensity score landmark analysis[J]. J Hepatol,2015,63(5):1190-1197.

[4] DOUMAS M,IMPRIALOS K,DIMAKOPOULOU A,et al. The role of statins in the management of nonalcoholic fatty liver disease[J]. Curr Pharm Des,2018,24(38):4587-4592.

[5] YI SW,KIM SH,HAN KJ,et al. Higher cholesterol levels,not statin use,are associated with a lower risk of hepatocellular carcinoma[J]. Br J Cancer,2020,122(5):630-633.

[6] BRAEUNING A,BUCHER P,HOFMANN U,et al. Chemically induced mouse liver tumors are resistant to treatment with atorvastatin[J]. BMC Cancer,2014,14:766.

[7] QIN WH,YANG ZS,LI M,et al. High serum levels of cholesterol increase antitumor functions of nature killer cells and reduce growth of liver tumors in mice[J]. Gastroenterology,2020,158(6):1713-1727.

[8] ZHAO Z,ZHONG L,HE K,et al. Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis[J]. Biochem Biophys Res Commun,2019,509(4):855-861.

[9] GBEL A,RAUNER M,HOFBAUER LC,et al. Cholesterol and beyond-The role of the mevalonate pathway in cancer biology[J]. Biochim Biophys Acta Rev Cancer,2020,1873(2):188351.

[10] CHOU CW,LIN CH,HSIAO TH,et al. Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis[J]. Sci Rep,2019,9(1):20403.

[11] KOPECKA J,TROUILLAS P,GAPAROVIC'ACCˇ，et al. Phospholipids and cholesterol:Inducers of cancer multidrug resistance and therapeutic targets[J]. Drug Resist Updat,2020,49:100670.

[12] ZHAO Y,WU TY,ZHAO MF,et al. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease[J]. J Biol Chem,2020,295(15):5152-5162.

[13] JIANG P,MUKTHAVARAM R,CHAO Y,et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells[J]. Br J Cancer,2014,111(8):1562-1571.

[14] PRASAD S,GUPTA SC,TYAGI AK. Reactive oxygen species(ROS)and cancer:Role of antioxidative nutraceuticals[J].Cancer Lett,2017,387:95-105.

[15] JANG HJ,HONG EM,KIM M,et al. Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2(Nrf2)activation through ERK and PI3K/Akt pathway in colon cancer[J]. Oncotarget,2016,7(29):46219-46229.

[16] GORABI AM,KIAIE N,HAJIGHASEMI S,et al. Statin-induced nitric oxide signaling:Mechanisms and therapeutic implications[J]. J Clin Med,2019,8(12):2051.

[17] ROSSONI LV,WAREING M,WENCESLAU CF,et al. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries[J].Clin Sci(Lond),2011,121(10):449-458.

[18] COLOTTA F,ALLAVENA P,SICA A,et al. Cancer-related inflammation,the seventh hallmark of cancer:Links to genetic instability[J]. Carcinogenesis,2009,30(7):1073-1081.

[19] RIDKER PM. From C-reactive protein to interleukin-6 to interleukin-1:Moving upstream to identify novel targets for atheroprotection[J]. Circ Res,2016,118(1):145-156.

[20] WEI TT,LIN YT,CHEN WS,et al. Dual targeting of 3-hydroxy-3-methylglutaryl coenzyme a reductase and histone deacetylase as a therapy for colorectal cancer[J]. EBio Medicine,2016,10:124-136.

[21] WIELAND E,RODRIGUEZ-VITA J,LIEBLER SS,et al. Endothelial Notch1 Activity facilitates metastasis[J]. Cancer Cell,2017,31(3):355-367.

[22] LIU S,UPPAL H,DEMARIA M,et al. Simvastatin suppresses breast cancer cell proliferation induced by senescent cells[J]. Sci Rep,2015,5:17895.

[23] KUBATKA P,KRUZLIAK P,ROTREKL V,et al. Statins in oncological research:From experimental studies to clinical practice[J]. Crit Rev Oncol Hematol,2014,92(3):296-311.

[24] KIMBUNG S,LETTIERO B,FELDT M,et al. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer[J].Oncotarget,2016,7(37):59640-59651.

[25] CHEN Y,KU H,ZHAO L,et al. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-Co A reductase feedback regulation[J]. Arterioscler Thromb Vasc Biol,2014,34(2):365-376.

[26] NISHIKAWA S,MENJU T,TAKAHASHI K,et al. Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection[J]. Cancer Manag Res,2019,11:3419-3432.

[27] MOON SH,HUANG CH,HOULIHAN SL,et al. p53 Represses the mevalonate pathway to mediate tumor suppression[J]. Cell,2019,176(3):564-580. e19.

[28] RAGHU VK,BECKWITT CH,WARITA K,et al. Biomarker identification for statin sensitivity of cancer cell lines[J]. Biochem Biophys Res Commun,2018,495(1):659-665.

施引文献

资源附件(0)

访问统计